Neurocrine Biosciences (NBIX) Return on Invested Capital (2020 - 2024)

Neurocrine Biosciences' Return on Invested Capital history runs 5 years deep, the most recent figure standing at 0.02% for Q4 2024.

• Quarterly Return on Invested Capital rose 2.0% year-over-year to 0.02% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.02% (up 2.0% YoY) and the FY2023 annual result came in at 0.01%, changed N/A from the prior year.
• Return on Invested Capital was 0.02% for Q4 2024 at Neurocrine Biosciences, up from 0.01% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.02% in Q4 2024 and bottomed at 0.0% in Q3 2020.
• A 5-year average of 0.01% and a median of 0.01% in 2020 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2021 — Return on Invested Capital changed 0 bps — and 2024, when it grew 2 bps.
• Neurocrine Biosciences' Return on Invested Capital stood at 0.01% in 2020, then jumped by 70 bps to 0.01% in 2021, then retreated by 30 bps to 0.01% in 2022, then plunged by 48 bps to 0.0% in 2023, then jumped by 420 bps to 0.02% in 2024.
• Business Quant data shows NBIX's Return on Invested Capital at 0.02% in Q4 2024, 0.01% in Q3 2024, and 0.01% in Q2 2024.